Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum...
Transcript of Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum...
![Page 1: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/1.jpg)
Pyoderma Gangrenosum: Treatment Options
Maria Aleshin, MDUCLA Dermatology
2‐18‐2018(special thanks to: Dr. Scott Worswick and Dr. Jennifer Hsiao)
![Page 2: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/2.jpg)
DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY
Maria Aleshin, MDU093 – Update on Management of Unusual Neutrophilic Dermatoses
DISCLOSURESI do not have any relevant relationships with industry.
![Page 3: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/3.jpg)
Outline
• Overview of pyoderma gangrenosum• Clinical presentation• Subtypes of pyoderma gangrenosum• Differential diagnosis• Systemic associations
• Topical treatments• Systemic treatments
![Page 4: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/4.jpg)
Background• Rare inflammatory neutrophilic dermatoses• Pathogenesis – poorly understood, neutrophil dysfunction• Age: 30‐50 yo• Sex: Females>Males (76%)• Location: Lower legs (78%)• Number of ulcers: >1 (65%)• Pathergy – (31% of cases)
Binus AM, et al. BJD. 2011.Uptodate.
![Page 5: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/5.jpg)
Clinical Presentation
• Begin as tender bump on skin or sterile pustule quickly progresses into painful ulcer
Uptodate.Brooklyn T, et al. BMJ. 2006.
24‐48 hrs
![Page 6: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/6.jpg)
Types of Pyoderma Gangrenosum
Fox L, et al. Leukemia and Lymphoma. 2006.Leger, et al. Derm Online Journal. 2011. Jin Y, et al. Dermatologica Sinica. 2015.
Brooklyn T, et al. BMJ. 2006Gameiro A, et al. Clin Cosmet Investig Dermatol. 2015.
Classic BullousIBD
Vegetative Peristomal
![Page 7: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/7.jpg)
240 pts with PG
95 pts misdiagnosed
Consider alternative diagnosis when refractory to treatment
Repeat biopsy
Weenig RH, et al. NEJM. 2002.
![Page 8: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/8.jpg)
Differential Diagnosis
Montero, E. Wounds. 2016. Branagan. Clin Ex Dermatol. 2009.
Weenig. NEJM. 2002. Vinicki. Rheumatology. 2013.
Emanuel PO. Indian Journal of Cancer. 2011.Ahronowitz. Am Jclin Dermatol. 2012.
Aviles‐Izquierdo JA, et al. Acta Derm Venereol. 2005.
Vascular occlusive disease Vasculittis
Cancer
InfectionFactitial
Inflammatory disease
![Page 9: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/9.jpg)
Diagnosis (of exclusion)
• No specific lab or histopathologic findings• Clinical history/physical exam• Review of Systems – to evaluate for underlying systemic conditions• Labs
• CBC, ESR, SPEP, ANCA, RF, antiphospholipid Abs• Colo/EGD (based on hx)• Biopsy – non‐specific
• Edema, neutrophilic infiltrate, necrosis and hemorrhage• Tissue culture – to r/o infection
Konopka CL. J Vasc Bras. 2013.
![Page 10: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/10.jpg)
PAPA• New entity coined in 2012
• Pyoderma gangrenosum• Acne• Suppurative • Hidradenitis
•Mutation not identified•May respond to IL‐1ß blockade
• First described in 1997• Pyogenic sterile• Arthritis• Pyoderma gangrenosum• Acne (nodulocystic type)
• Autosomal Dominant•Mutation in PSTPIP1
• Increase Il‐1ß
PASH
Braun‐Flaco, et al. JAAD. 2012.Lindor N, et al. Mayo Clinic Proc. 1997.
![Page 11: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/11.jpg)
Case #1• 23 yo F presented with 1‐month history of an ulcer on the lower extremity• Painful 10/10• +Pathergy
• PMH: SLE •Meds: • Azathioprine• Plaquenil
• SH: undergraduate student• FH: non‐contributory
![Page 12: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/12.jpg)
![Page 13: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/13.jpg)
Which of the following is NOT commonly associated with PG?
A. Inflammatory bowel diseaseB. DepressionC. Thyroid DiseaseD. Hematologic disordersE. Arthritis
![Page 14: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/14.jpg)
Systemic Associations
• Systemic conditions (1/2 of cases)• IBD (34%)• Hematologic disorders (20%)• Arthritis (19%)• Depression (19%)• Psoriasis (11%)• Hepatitis (9%)• CTD/SLE• Behcet disease• HIV• Pregnancy
Binus AM. BJD. 2011.
![Page 15: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/15.jpg)
Patient declines systemic therapy… Now what?
• Can topical therapy be used alone for the treatment of PG?• Topical corticosteroids and tacrolimus (0.03% or 0.1%) • 43.8% healed on topical medication alone, 33.3% concomitant systemics
• Median time to healing 145 days• Initial ulcer size was a predictor of time to healing• Apply to inflamed ulcer edge • Caution with topical tacrolimus (systemic absorption)
• Bottom line: Yes, topical corticosteroids or tacrolimus can be used for small localized lesions.
Le Cleach. JAMA Derm. 2011.Thomas K. JAAD. 2016.
Topical Therapy!
![Page 16: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/16.jpg)
Intralesional Triamcinolone• Triamcinolone 6mg‐40mg/cc• Inject ulcer edge• q4‐6 weeks•Monitor closely for signs of pathergy
Goldstein F. J Clin Gastroenterol. 1985.Jennings JL J Am Acad Dermatol. 1983.
![Page 17: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/17.jpg)
Case Continued
• Patient started on clobetasol 0.05% ointment daily x 3 months• Ulcer no longer painful, growing, or with surrounding erythema however still present
•What is the next best step in management?
![Page 18: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/18.jpg)
Becaplermin• Recombinant PDGF
• FDA approved for diabetic ulcers
• Black box warning • Becaplermin 0.01% gel• Apply to ulcer edge• 2 published reports of using becaplermin for PG
Braun‐Falco, et al. BJD. 2002. Freedman, et al. Adv Skin Wound Care. 2002.
Cost: 1000‐1100$/15gm tube
![Page 19: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/19.jpg)
Topical Timolol• ß2‐adrenergic receptor antagonist• Timolol 0.5% gel or solution• 1 drop every 2 cm to ulcer edge• MOE: improves keratinocyte migration
• Case report (Liu et al)• 77 yo F p/w painful, ulcer on right medial ankle
• Collagenase 250U/g ointment and timolol 0.05% gel (to edge)
• After 36 days completely re‐epithelialized
Moreira C, et al. BMJ Case Rep. 2017.Liu, et al. JAAD. 2014.
Braun, et al. JAMA Derm. 2013.
![Page 20: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/20.jpg)
Other Topical Agents• Dapsone• Cyclosporine• 5‐Aminosalicylic acid• 1% sodium cromoglycate• Nitrogen mustard
Handler MZ, et al. Drugs Dermatol 2011.Azizan, et al. Med J of Malayasia. 2008.
![Page 21: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/21.jpg)
Local Wound Management• Avoid wet‐dry dressings• Careful with enzymatic debridement•Moisture‐retentive dressings (iehydrogels)• Induce collagen production• Facilitate autolytic debridement• Promoted angiogenesis• Less permeable to external infection
• Exudative wounds• Alginates necessary to reduce risk of maceration
Miller J, et al. JAAD. 2010. Fonder MA, et al. JAAD. 2008.
![Page 22: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/22.jpg)
Patient would like to undergo an elective breast augmentation, how should you counsel the patient?
• Retrospective study ‐ Brigham and Women’s and Mass Gen Hospital from 2000‐2015
• 5.5% risk of PG by procedure (33 developed PG/601 surgeries)• 15.1% of patients experienced postsurgical recurrence/exacerbation• Risk increased with more invasive procedures and chronic PG• Immunosuppression, time elapsed since original PG diagnosis, and procedure location did not significantly influence risk
• Risk is low, but certainly significant given invasive nature of procedure
Xia FD, et al. JAAD. Accepted 2018.
![Page 23: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/23.jpg)
Case #2• 79 yo M with h/o MGUS
• Cyst on right knee I&D • Rapidly progressed to painful ulcer• Clinically consistent with PG
• ROS: Night sweats and hemoptysis• CT scan showed mass‐like pulmonary consolidations• Lung biopsy – acute inflammation and necrosis • Extracutaneous PG
Two, et al. Dermatol Ther. 2016.
![Page 24: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/24.jpg)
Which organ is most commonly affected in extracutaneous PG?A. EyesB. Upper airwayC. LungD. LiverE. Bone
![Page 25: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/25.jpg)
Extracutaneous PG• Typically follows skin lesions• Lung is most common
• SOB, hemoptysis• Upper airway, spleen, eyes, bone, muscle
Gade, et al. Respiratory Medicine. 2015.Reichrath J, et al. JAAD. 2005.
![Page 26: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/26.jpg)
What is a reasonable first line therapy for this patient?
• Prednisone 1‐2mg/kg/day• Cyclosporine 3‐5mg/kg/day
• May be better for patients with idiopathic disease
Miler J, et al. JAAD. 2010.
![Page 27: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/27.jpg)
Which of the two is better?
• STOPGAP: Multicenter, blinded, RCT• Prednisolone 0.75 mg/kg/d vs. cyclosporine 4mg/kg/d • At six months:
• Cyclosporine: 28/59 (47%) – ulcers healed• Prednisolone: 25/53 (47%) – ulcers healed
• Adverse reactions similar for both groups (2/3 of pts)• Bottom line: No statistical difference in outcomes
Ormerod A, et al. BMJ 2015.
![Page 28: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/28.jpg)
What is the only medication that has undergone a randomized placebo controlled trial?A. AdalimumabB. CyclosporineC. PrednisoneD. InfliximabE. IVIG
![Page 29: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/29.jpg)
Infliximab• Only randomized, placebo‐controlled trial of systemic therapy for PG• Infliximab 5mg/kg vs Placebo •Week 2: 46% of infliximab improved, 6% in placebo• Total of 29 patients got infliximab, 69% had beneficial clinical response• 67% with IBD respond, 73% without IBD respond
Brooklyn TN, et al Gut. 2006.
![Page 30: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/30.jpg)
TNF‐alpha Inhibitors• Infliximab• Adalimumab
• 40mg weekly• 40mg twice monthly
• Etanercept• 25mg‐50mg twice weekly
• Hx of IBD or RA• Fonder et al ‐ patient failed infliximab, responded to adalimumab Lee, JH, et al. Ann Dermatol. 2017.
Roy DB, et al. JAAD. 2006.Fonder MA, et al. J Burns Wounds. 2006.
![Page 31: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/31.jpg)
Anakinra• Interleukin receptor 1 antagonist
• Lowers levels of IL‐1β• Shown to be effective in PAPA and PAPASH• Recent case series of 3 patients successfully treated with anakinra (with RA and SLE)• Dose: Anakinra 100mg sq daily• Rapid response within days!!
Beynon C, et al. Journ of Clin Rheum. 2017.Brenner M, et al. BJD. 2009.
![Page 32: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/32.jpg)
The patient has tried and failed prednisone, cyclosporine, and a TNF‐alpha inhibitor. What else can you try?• Systematic review investigated treatment of refractory PG with IVIG •Majority also receiving systemic glucocorticoids (88%)• Complete response: 26/49 patients (53%)• Complete/Partial response: 43/49 (88%)•Mean time to initial response 3.5 weeks• 92% of patients tapered off of steroids while on IVIG
Song H, et al. BJD. 2017.
![Page 33: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/33.jpg)
What can you try for rapidly progressing PG?• Methylprednisolone 1gm IV x 1‐5 days• Cyclosporine 3‐5mg/kg IV x 7 days
Turner RB, et al. JAAD. 2010.
![Page 34: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/34.jpg)
Combination Therapy• Retrospective, multicenter cohort study out of Germany, looked at 121 patients with PG• 88.5% of patients initially responded to glucocorticoids, however majority eventually required additional agent
• PG healed in 72.7% of patients• Mean healing time was 7.1 months• On average – patients required 2 (or more) different systemic therapies
Herberger K, et al. BJD. 2016.
![Page 35: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/35.jpg)
Other Systemic Therapy• Dapsone (if normal G6PD levels)• Mycophenolate mofetil (good adjunct therapy)• Methotrexate (good adjunct therapy)• Minocycline (good if you suspect underlying infection)• Ustekinumab• Azathioprine• Tacrolimus• Thalidomide• Cyclophosphamide• Chlorambucil• Alefacept Turner RB, et al. JAAD. 2010.
Berth‐Jones J, et al Journal of Dermatologic Treatment. 1989.Goldminz AM, et al. JAAD. 2012.
Miller J, et al. JAAD. 2010.
After ustekinumab
![Page 36: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/36.jpg)
Pain Control
• Debilitating pain• Important to monitor patient’s level of pain as marker of treatment efficacy•Multispecialty approach is often helpful to address chronic pain • Screen for depression
Wollina U, et al. Orphanet J of Rare Dis. 2007.Miller J, et al. JAAD. 2010.
![Page 37: Pyoderma Gangrenosum: Treatment Options U093... · Outline •Overview of pyoderma gangrenosum •Clinical presentation •Subtypes of pyoderma gangrenosum •Differential diagnosis](https://reader031.fdocuments.in/reader031/viewer/2022022805/5ca19f8488c99318568bd074/html5/thumbnails/37.jpg)
Summary• Consider alternative diagnosis if PG not responding to treatment• If the ulcer is small, localized, or vegetative subtype –consider topical therapy • Becaplermin and timolol can be useful for wound advancement• IVIG for refractory disease•Multiple systemic agents often required• Pain control, screen for depression